Clinical Trials
171
11 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1869
Active, not recruiting
3
1.8%
Completed
131
76.6%
Enrolling By Invitation
3
1.8%
Not yet recruiting
5
2.9%
Recruiting
17
9.9%
Suspended
1
0.6%
Terminated
5
2.9%
Unknown
6
3.5%
No approval data available
- Intellicule, a Purdue University-affiliated software startup, secured a $217,941 SBIR Phase I grant from the National Institutes of Health to develop advanced biomolecular modeling software. - The company's deep learning-powered technology aims to overcome current limitations in cryo-EM analysis, particularly when resolution is worse than 3 angstroms, making drug discovery more accessible to non-specialists. - The software enables detection of atoms in low-resolution cryo-EM images and could accelerate novel drug development by providing precise structural information to guide molecular design with improved efficacy.
- Researchers at Purdue University and Merck have developed a patent-pending Raman spectroscopy-based tool that monitors vaccine quality in real-time during production, delivering results in 30 seconds or less. - The tool successfully detected human cytomegalovirus particles at industrially relevant concentrations and flow rates, representing the first reported Raman spectroscopy system of this type for CMV detection. - Unlike current offline testing methods that require sample removal from production lines, this online monitoring system operates continuously during manufacturing, potentially saving time and money in vaccine production. - The technology supports continuous manufacturing processes and could be adapted for monitoring other vaccine types and viral particles in future applications.
- GeniPhys has received FDA 510(k) clearance for Collymer Self-Assembling Scaffold (SAS), a novel two-part flowable wound management device that forms scaffolds through in situ collagen self-assembly. - The device is indicated for managing diverse wound types including partial- and full-thickness wounds, skin ulcers, surgical wounds, and trauma wounds, addressing critical unmet needs for millions of patients. - The technology, developed at Purdue University and backed by over a decade of peer-reviewed research, overcomes limitations of conventional implantable materials by adapting to complex wound geometries. - GeniPhys is now raising capital for commercialization and pursuing strategic partnerships to accelerate product launch in the advanced wound care market.
- LyoWave Inc. received a $304,436 Phase I SBIR grant from the National Science Foundation to advance its high-frequency microwave heating technology for pharmaceutical lyophilization. - The company's technology uses tunable microwave frequencies in the tens of gigahertz range to accelerate freeze-drying processes while maintaining product stability and uniformity. - LyoWave has partnered with Millrock Technology and secured additional funding from Indiana Economic Development Corp., positioning the company to scale from laboratory innovation to commercial manufacturing. - The technology could significantly reduce manufacturing costs and increase availability of injectable pharmaceuticals, vaccines, and diagnostic reagents by shortening drying cycles and improving energy efficiency.
- Eli Lilly and Purdue University have announced an expanded collaboration worth up to $250 million to advance pharmaceutical research and development across multiple therapeutic areas. - The strategic partnership aims to combine Lilly's industry expertise with Purdue's academic research capabilities to address unmet medical needs and accelerate drug discovery timelines. - This investment represents one of the largest industry-academic collaborations in the pharmaceutical sector, with funds directed toward establishing new research facilities and supporting joint scientific initiatives.
- Eli Lilly has extended its research collaboration with Purdue University through 2032, investing up to $250 million over the next eight years in what could become the largest industry-academic partnership in the United States. - The expanded alliance will facilitate researcher exchanges between Purdue's campus and Lilly's Indianapolis facilities, while also utilizing Indiana's LEAP Research and Innovation District to accelerate drug discovery and development. - This partnership represents a significant investment in pharmaceutical innovation infrastructure, focusing on improving both drug discovery processes and manufacturing capabilities in the U.S.
- Eli Lilly and Purdue University have announced a landmark collaboration worth up to $250 million over eight years, potentially becoming the largest industry-academic agreement of its kind in the United States. - The Lilly-Purdue 360 Initiative will focus on accelerating drug discovery through AI, enhancing clinical development pathways, improving manufacturing with robotics, and developing specialized workforce talent. - This expanded partnership, extending through 2032, will create research opportunities across multiple locations including Purdue's campus and Lilly's facilities in Indianapolis and the LEAP Research and Innovation District.
- Eradivir has initiated a Phase 2 human challenge study for EV25, a novel antiviral therapeutic, following successful Phase 1 results showing the compound was well-tolerated in healthy participants. - The study will evaluate up to 60 healthy adults deliberately infected with influenza, with data expected by September 2025, potentially leading to a larger Phase 2b trial involving 375 participants during the 2025-26 flu season. - Preclinical research demonstrated EV25's ability to eliminate influenza virus in lungs even 96 hours post-infection and effectiveness against multiple flu strains, including pandemic variants and those resistant to current treatments.
- Eli Lilly commits $42.5M to establish a new pharmaceutical manufacturing scholarship program at Purdue University, supporting 75-100 students annually with full tuition and guaranteed internships. - The partnership allocates $50M for research collaborations focusing on genetic medicines, intrathecal delivery systems, and nanoparticle drug delivery technologies over five years. - The investment aims to strengthen Indiana's life sciences sector while addressing manufacturing challenges in emerging fields like gene and cell therapy.
